News | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.

All posts in News

Dr. Stephen B.H. Kent to receive the Meienhofer Award at BPS 2022

The Meienhofer Award was established in 2007 to recognize an individual with a lifetime of achievement in peptide science. The biennial award is named after Johannes Meienhofer, in honor of his transformative discoveries in solid phase peptide synthesis. Notably, Meienhofer's work demonstrated the power of medicinal chemistry in peptide pharmacology and is considered to have laid the foundation of modern synthetic peptide therapeutics.

Stephen B. H. Kent

Stephen B. H. Kent, recipient of the 2022 Meienhofer Award, received his first two university degrees in his native New Zealand and his Ph.D. (Organic Chemistry) from University of California, Berkeley. Following postdoctoral work with Bruce Merrifield, Professor Kent held faculty appointments at the Rockefeller University, the California Institute of Technology, and The Scripps Research Institute. He was Founder of Gryphon Sciences and served as its Chief Scientific Officer from 1997-2000. In 2001, he joined the faculty of the University of Chicago, where since June 2021 he is Professor Emeritus of Chemistry, Biochemistry and Molecular Biology.

Over the past several decades, Stephen Kent has profoundly shaped the field of peptide and protein chemistry. His many and diverse contributions have altered the way scientists tackle the study of these macromolecules. He pioneered the total chemical synthesis of protein molecules and showed it to be a practical and versatile method for the production of large quantities of high purity material for detailed mechanistic and structural investigations. In particular, the Kent chemical ligation concept together with the native chemical ligation reaction made proteins and enzymes accessible to direct chemical investigation via convergent, chemoselective assembly of unprotected synthetic peptide segments.

Since its introduction in 1994, native chemical ligation has become robust, reliable, and widely used. Efficient total chemical synthesis of a wide range of protein molecules, including the enzymes HIV-1 protease and human lysozyme, the protein hormone human insulin, glycoprotein mimetics of erythropoietin, together with numerous mirror image protein molecules for his pioneering studies of racemic protein crystallography, highlight the practical utility of such approaches. As these examples attest, Stephen Kent has had a gift, throughout his career, for developing new chemistries and for utilizing them to reveal the molecular basis of protein function.

His exceptional achievements in scientific research have previously been recognized by the receipt of major distinctions, including the ACS Hirschmann Award in Peptide Chemistry (1994), the Protein Society E.T. Kaiser Award (2002), the Vincent du Vigneaud (2004) and R. Bruce Merrifield (2009) Awards of the American Peptide Society, the European Peptide Society Rudinger Medal (2010), the Japanese Peptide Society Akabori Medal (2010), the ACS Alfred Bader Award in Bioorganic Chemistry (2011), the Lorne Symposium Leach Medal (2013), the ETH Prelog Medal (2017), and the inaugural Scoffone Award of the Italian Peptide Society (2018).

Dr. Kent will receive his award Tuesday, November 8th during the Boulder Peptide Symposium. Register today!

More information on the Meienhofer Award, including a list of previous recipients, and the Boulder Peptide Symposium can be found online at www.boulderpeptide.org/meienhofer-award.

Scottish scientists say venom from sea snails could hold key to future painkillers

The cone snail’s venom contains chemicals called conotoxins, which the creature uses to paralyse its prey by blocking parts of their nervous system. Scientists believe a modified version of the poison could form the basis of future drugs capable of blocking pain receptors in the human body.

Read more at www.scotsman.com

Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning

BOSTON--(BUSINESS WIRE)--Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon Denominator and the Mytide founding team. As part of the financing, Alloy Therapeutics CEO Errik Anderson will join Mytide’s Board of Directors. This financing will allow Mytide to scale its AI-enabled Gen2 platform to support cost-effective, scalable, and decentralized manufacturing for a wide-variety of peptide and peptide conjugate applications for therapeutic discovery and personal peptide vaccines (PPV).

READ FULL NEWS RELEASE

Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies

Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.

READ FULL NEWS RELEASE

FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to all therapeutic targets, including those previously considered “undruggable,” today announced the selection of its lead product development candidate, FOG-001, a first-and-only-in-class direct β-catenin inhibitor. FOG-001 represents the first of FogPharma’s proprietary, conformationally hyperstabilized α-helical polypeptides (Helicon polypeptides), a new class of therapeutics designed to combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.

READ FULL ARTICLE ON BUSINESS WIRE

9 Meters Biopharma Provides Clinical Update on Two Late-Stage Pipeline Products for Short Bowel Syndrome and for Celiac Disease

RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today an update on its late stage pipeline products vurolenatide, a proprietary long-acting glucagon-like peptide (GLP-1) agonist in a Phase 2 trial for adults with short bowel syndrome (SBS), and larazotide, a gut-selective tight junction modulator in a Phase 3 trial for celiac disease.

READ THE FULL PRESS RELEASE

Review: Cyclic peptide drugs approved in the last two decades (2001–2021)

In contrast to the major families of small molecules and antibodies, cyclic peptides, as a family of synthesizable macromolecules, have distinct biochemical and therapeutic properties for pharmaceutical applications. Cyclic peptide-based drugs have increasingly been developed in the past two decades, confirming the common perception that cyclic peptides have high binding affinities and low metabolic toxicity as antibodies, good stability and ease of manufacture as small molecules. Natural peptides were the major source of cyclic peptide drugs in the last century, and cyclic peptides derived from novel screening and cyclization strategies are the new source. In this review, we will discuss and summarize 18 cyclic peptides approved for clinical use in the past two decades to provide a better understanding of cyclic peptide development and to inspire new perspectives. The purpose of the present review is to promote efforts to resolve the challenges in the development of cyclic peptide drugs that are more effective.

DOI: 10.1039/D1CB00154J (Review Article) RSC Chem. Biol., 2022, 3, 18-31

9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)

RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the journal Critical Care Explorations, accessible online here, on the use of larazotide to treat pediatric patients with multisystem inflammatory syndrome in children (MIS-C) resulting from COVID-19. MIS-C is a rare but severe and potentially life-threatening condition that usually develops in children weeks to months after they have experienced a mild or even asymptomatic case of COVID-19.

READ FULL PRESS RELEASE

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

HARRISON, N.Y., Jan. 6, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today the initiation of Phase 2 and dosing of the first patient in the glioblastoma (GBM) expansion cohort in the ongoing Phase 1-2 Study of ST101.  

The expansion cohorts in the study include patients with refractory, locally advanced and metastatic cutaneous melanoma, hormone-receptor-positive breast cancer, castrate-resistant prostate cancer, and GBM, and are designed to determine proof-of-concept efficacy of ST101 and provide further insights into safety, pharmacokinetics (PK) and pharmacodynamics (PD).  

READ MORE AT SAPIENCE THERAPEUTICS PRESS RELEASE

Novo Nordisk launches anti-diabetes pill semaglutide in India

Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.

The oral semaglutide will cost Rs 315 per pill or around Rs 10000 for a full month treatment.

"We have kept it at the (similar) price range of the injectable GLP-1, not only that we have followed price equilibrium band, which means if a person goes from 3 mg to 7 mg, the cost they pay is just 9-10% higher, and not double, as per conventional models ..

Read more at:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/novo-nordisk-launches-anti-diabetes-pill-semaglutide-in-india/articleshow/89024394.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst


s2Member®
loading...